

1 **Quality of life profile of methadone maintenance treatment patients in Ho Chi**
2 **Minh City, Vietnam**

3

4 **Authors:**

5 Vu Thu Trang^{a,*}, Le Ngoc Tu^{b,*}, Vu Thi Tuong Vi^c, Khuong Quynh Long^a, Le Huynh Thi Cam
6 Hong^{c,d}, Tieu Thi Thu Van^e, Do Van Dung^{c,d}

7 *These authors contribute equally to this work and act as co-first authors

8

9 ^a*Hanoi University of Public Health, Vietnam*

10 ^b*Department of Disease Control and Prevention, Pasteur Institute of Ho Chi Minh City, Vietnam*

11 ^c*Vietnam HIV Addiction Technology Transfer Center - University of Medicine and Pharmacy at*
12 *Ho Chi Minh City, Vietnam*

13 ^d*University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam*

14 ^e*Prevention HIV/AIDS Center Ho Chi Minh City HIV/AIDS Association, Vietnam*

15

16

17 **Corresponding author:**

18 Vu Thi Tuong Vi

19 Vietnam HIV Addiction Technology Transfer Center - University of Medicine and Pharmacy at
20 Ho Chi Minh City, Vietnam, 217 Hong Bang Street, Ward 11, District 5, Ho Chi Minh City,
21 Vietnam.

22 Phone: +84 (0) 908 577 767; Email: tuongvipac@gmail.com

23

24

25 **Declarations**

26 **Ethics approval and consent to participate**

27 All procedures performed in studies involving human participants were in accordance with the
28 ethical standards of The Institution Review Board of Ho Chi Minh City HIV/AIDS Center (IRB-
29 02-2018, dated 10/08/2018). All participants provided signed informed consent.

30 **Consent for publication**

31 Not applicable.

32 **Availability of data and material**

33 Available upon request to the corresponding author

34 **Conflict of interest**

35 No potential conflict of interest was reported by the authors.

36 **Funding**

37 This study was supported by the South Vietnam HIV Addiction Technology Transfer Center and
38 Ho Chi Minh City HIV/AIDS Center

39 **Authors' contributions**

40 VTT: Conducted data analysis and result explanation, drafted the manuscript

41 LNT: Collected the data, conducted data analysis and result explanation, drafted the manuscript

42 KQL: Designed the study, conducted data analysis and result explanation, provided editorial input

43 VTTV: Designed the study, provided editorial input

44 LHTCH: Participated in study design, provided editorial input

45 TTTV: Participated in study design, provided editorial input

46 DVD: Participated in study design, provided editorial input

47 All authors read and approved the final manuscript.

48

49 **Acknowledgements**

50 The authors would like to thank all MMT patients who participated in this study, colleagues in the
51 South Vietnam HIV Addiction Technology Transfer Center and Ho Chi Minh City HIV/AIDS
52 Center, District 4 and District 8 MMT clinics for supporting this research.

53

54 **Quality of life profile of methadone maintenance treatment patients in Ho Chi**
55 **Minh City, Vietnam**

56

57 **Abstract**

58 **Aim:** To determine the health-related quality of life (HRQoL) of methadone maintenance
59 treatment patients in Ho Chi Minh City, Vietnam.

60 **Subject and Methods:** A cross-sectional study was conducted in 967 patients treating at two
61 methadone clinics in Ho Chi Minh City, in 2018. Patient's health-related quality of life was
62 estimated using the EQ-5D-5L and Visual analogue scale (VAS). Tobit regressions were used to
63 identify factors related to patient's health-related quality of life.

64 **Results:** Overall, the mean EQ-5D-5L utility and EQ-VAS indexes were 0.96 (SD = 0.12) and
65 75.8 (SD=15.5), respectively. Factors related with a higher EQ-5D-5L score included peoples who
66 are single, and have a higher monthly income (more than 4 million VND per month), while patients
67 aged under 30 years old, have full-time employment, and have higher education were associated
68 with a higher EQ-VAS score. HIV was associated with lower scores of both EQ-5D-5L and EQ-
69 VAS ($\beta = -0.07$ (95%CI: -0.13; -0.01), and $\beta = -7.10$ (95%CI: -9.23; -4.98), respectively).

70 **Conclusion:** HRQoL measurement provides valuable information for the policymaker to adopt
71 suitable decisions on opioid dependence treatment. The finding shows that patients with education,
72 job situation, and socioeconomic status are the related elements with higher HRQoL, which
73 suggested that the policymakers and physicians should pay more attention to these aspects while
74 working on treatment plan for drug users.

75 **Key words:** *HRQoL, methadone maintenance treatment, quality of life, Vietnam*

76 **Introduction**

77 Since the first introduction in 1947, Methadone maintenance treatment (MMT) has been proved
78 as an efficacious drug treatment modality for heroin addiction (Herget 2005; O'Donnell and
79 Vogenberg 2011; World Health 2004). In Vietnam, the MMT program was originated in 2008,
80 with approximately 53,000 drug users have received treatment in 336 nationwide MMT clinics up
81 to 31th December 2019 (Nguyen et al. 2017c). Coverage of the MMT program in Vietnam had
82 reached 28% of the total number of people addicted to opiates, treatment adherence rate after six
83 months was 83%, corresponding to the graded good (by World Health Organization standard is
84 80%). Methadone treatment in Vietnam has been shown to be effective in helping patients reduce
85 and eventually stop using illegal drugs, improve health (reduce HIV infection and diseases
86 transmitted through blood, physical enhancement, physical and mental rehabilitation) (MOH
87 2020).

88 Health-related quality of life (HRQoL) is a multidimensional construct related to the physical,
89 mental, emotional, and social functioning of an individual, based on their perceptions. HRQoL is
90 becoming increasingly important in assessing treatment outcomes since most opioid-dependent
91 people often experience negative socioeconomic consequences and social exclusion, let alone
92 suffer from adverse health outcomes and high rates of overdose deaths (Strada et al. 2017). Several
93 studies have found the opioid users or those receiving MMT tend to have impaired HRQoL caused
94 by their comorbid infectious diseases, such as hepatitis B virus (HBV), hepatitis C virus (HCV),
95 and HIV (Astals et al. 2008; Korthuis et al. 2008). For instance, Astals et al. conducted a study to
96 assess the quality of life between the general European population and opioid users, the result
97 found that the former group had significantly lower scores compared to the general population
98 (Astals et al. 2008). Other studies used the patient's HRQoL as outcome indicator to evaluate the

99 effectiveness of MMT program (Karow et al. 2011; Lashkaripour et al. 2012; Strada et al. 2017).
100 For example, research conducted in HCMC and Hai Phong showed the number of patients with
101 good HRQoL increased from 16% to 55% after 3 months of treatment (Vietnamese Ministry of
102 Health 2014).
103 Although many studies have explored the HRQoL of opioid users, only a few have examined
104 variations in their scores and determinants factors (Korthuis et al. 2008; Nguyen et al. 2017b;
105 Quyen et al. 2020). A comprehensive understanding of the relationships between HRQoL and
106 MMT is important for developing response strategies to the opioid. This is especially of
107 importance in the context of Vietnam, there are little shreds of evidence that summarize specific
108 linking associated factors to the quality of life for people with opioid dependence. This study was
109 conducted to examine the HRQoL and its determinants among MMT patients in Ho Chi Minh
110 City, Vietnam.

111 **Method**

112 *Setting and participants*

113 This cross-sectional study was conducted at two MMT clinics in District 8 and District 4, Ho Chi
114 Minh City (HCMC). The inclusion criteria for the survey included: (1) ≥ 18 year olds, (2) currently
115 visiting the clinic during the study period and (3) having the ability to answer the questionnaire.
116 There were 1,039 eligible patients in two clinics, among them, 967 people (93.1%) agreed and
117 participated in the study.

118 *Procedure and measurement*

119 Patients who met the inclusion criteria were invited to private rooms. Subsequently, they were
120 given the verbal introduction of the study and confirmed their enrollment by signing the consent
121 form. Those who refused to participate continued their usual treatment at the clinic. The

122 questionnaire was conducted by face-to-face interviews in around 25-30 minutes. Data collectors
123 were well-trained preventive medicine doctors from Addiction Technology Transfer Center,
124 University of Medicine and Pharmacy at Ho Chi Minh City. Clinic staffs were not involved in this
125 process to avoid potential bias.

126 ***Outcome variables***

127 The primary outcome of this study was quality of life measured by The EuroQol-five (EQ-5D-5L)
128 and The Visual Analogue Scale (EQ-VAS). The EQ-5D-5L includes five dimensions which
129 describe different aspects of life: mobility, self-care, usual activities, pain/discomfort, and
130 anxiety/depression. In each dimension, a Likert rating scale of five response levels (no problems-
131 code 1, slight problems-code 2, moderate problems-code 3, severe problems- code 4, unable
132 to/extreme problems-code 5) is used. The numbers for each dimension can be combined to a 5-
133 digit code ranging from 11111 (no problems) to 55555 (worst health). The overall EQ-5D-5L score
134 is calculated by using the crosswalk value set in the data of EuroQoL (EuroQol Research
135 Foundation 2019).

136 The Visual Analogue Scale (EQ-VAS) is developed to assess the self-rated health of patients. The
137 scale ranges from 0 (*the worst health you can imagine*) to 100 points (*the best health you can
138 imagine*) (EuroQol Research Foundation 2019). The Vietnamese version of EQ-5D-5L and EQ-
139 VAS have been translated, validated and used in many previous studies in Vietnam (Nguyen et al.
140 2017a; Tran et al. 2018; Tran et al. 2012).

141 ***The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST)***

142 The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST) was included to
143 investigate the risk of concurrent drug use among respondents. The ASSIST was developed by the
144 World Health Organization (WHO) and designed to be culturally neutral and useable in primary

145 care setting across a variety of cultures. The tool contains a total of 8 questions collecting
146 information about lifetime use of 9 common substances, use of these substances and associated
147 problems over the last 3 months. Patients being assessed as “*medium risk*” or “*high risk*” were
148 defined as hazardous substance users (World Health Organization (WHO) 2010).

149 *Clinical data extraction*

150 MMT treatment information of participants including duration on MMT, daily methadone dosage,
151 number of doses missed within last 3 months and comorbidities (HIV, tuberculosis, hepatitis B,
152 and hepatitis C) were extracted from the medical records.

153 Urine samples of respondents were collected and tested for methamphetamine (a substance of ATS
154 group) using rapid urine test (ABON, Biopham Co. Ltd). This process was implemented by well-
155 trained laboratory staffs.

156 *Data analysis*

157 Descriptive statistics were used to summarize the data, with frequencies and percentages for
158 categorical variables and means with standard deviations (SD) or median with inter-quartile ranges
159 (IQR) for quantitative variables. To detect the differences between EQ-5D-5L and EQ-VAS scores
160 among respondents, we used t-tests, ANOVA tests or Wilcoxon Rank Sum tests when appropriate.
161 Tobit regressions were conducted to identify factors associated with EQ-5D-5L and EQ-VAS
162 scores. A significant level of $p < 0.05$ was used for all statistical tests. All analyses were carried
163 out using Stata v16 (Stata Corp, College Station, TX).

164 *Ethics*

165 All procedures performed in studies involving human participants were in accordance with the
166 ethical standards of the Institution Review Board of Ho Chi Minh City HIV/AIDS Center (IRB-
167 02-2018, dated 10/08/2018). All participants provided signed informed consent.

168 **Results**

169 A total of 967 participants enrolled into the study. Patients' demographic characteristics are shown
170 in Table 1. Most of participants were male (89.9%), aged from 30 to 49 (81.8%), having full-time
171 job (74.3%) and being married or living with partners (46.4%). Nearly a half of respondents
172 (47.8%) finished secondary school and had a monthly income from 4 to 8 million VND (44.8%).
173 The majority of patients had ever injected drugs (78.0%), while only 12.4% respondents still
174 injected drugs within the past three months. About 60% of them had the duration on MMT
175 between 1 to 5 years, with prevalent dose for methadone was 60-120 mg/day (41.2%). Moreover,
176 44.8% participants reported missing at least one dose in past 3 months. The proportions of
177 participants with positive HIV, HBV, HCV and tuberculosis were 33.9%, 9.7%, 41.9% and 1.0%,
178 respectively.

179 **(Table 1 is about here)**

180 Table 2 shows profiles of EQ-5D-5L domains according to frequencies of each item response. The
181 highest proportion of respondents reporting any problems was in pain/discomfort domain (14.2%),
182 followed by anxiety/ depression (14.1%), usual activities (7.2%) and mobility (6.7%), the lowest
183 percentage was in Self-care (2.8%).

184 **(Table 2 is about here)**

185 The mean EQ-5D-5L utility scores and EQ-VAS scores by different characteristics are
186 summarized in table 3. Overall, the mean EQ-5D-5L and EQ-VAS indexes were 0.96 (SD=0.12)
187 and 75.8 (SD=15.5), respectively. Lower EQ-5D-5L and EQ-VAS scores were found older
188 patients and those having lower education, and having unstable job. Patients who had monthly
189 income under 4 million VND had lower EQ-5D-5L and EQ-VAS indexes compared to other groups
190 ($p < 0.001$). We also found significant differences on EQ-5D-5L and EQ-VAS scores in term of

191 duration on MMT, daily methadone dose, dose missed in the last 3 months. Notably, people being
192 positive with HIV, hepatitis B, C or having ARV treatment also had lower EQ-5D-5L score or EQ-
193 VAS index than their counterparts.

194 **(Table 3 is about here)**

195 Table 4 shows the association between EQ-5D-5L and EQ-VAS scores and different kinds of
196 substance use. Patients being hazardous ATS and cannabis users had 5 points and 7 points lower
197 than the others in EQ-VAS index, respectively ($p < 0.001$ for ATS use and $p = 0.043$ for cannabis
198 use).

199 **(Table 4 is about here)**

200 Table 5 illustrates ten most common EQ-5D-5L health states, which accounted for 91.3% of
201 participants. Health conditions “11111” (full health), “11112” (slightly problems in
202 anxiety/depression) and “11121” (slightly problems in pain/discomfort) were the most frequent
203 statuses among respondents.

204 **(Table 5 is about here)**

205 The final multivariate model revealed four factors related to EQ-5D-5L scores. Patients who were
206 married/live with partners and those who were divorced/separated/widowed had lower EQ-5D-5L
207 scores, compared with patients who were single, ($\beta = -0.08$; 95%CI: -0.14,-0.01 and $\beta = -0.09$;
208 95%CI: -0.17,-0.01, respectively). Similarly, the lower scores were found in patients who had
209 unstable job compared to those having full-time job ($\beta = -0.10$; 95%CI: -0.19,-0.01 in part-time job
210 and $\beta = -0.09$; 95%CI: -0.18,-0.01 in unemployed) or being positive with HIV ($\beta = -0.07$; 95%CI: -
211 0.13,-0.01). By contrast, patients had higher EQ-5D-5L score when they got higher monthly
212 income ($\beta = 0.12$; 95%CI: 0.04,0.20 in 4-8 million VND and $\beta = 0.12$; 95%CI: 0.02,0.21 in >8
213 million VND).

214 Similar results were found in the final model for EQ-VAS scores. The lower EQ-VAS scores were
215 found in patients having unstable job as compared to those having full-time job ($\beta=-4.24$; 95%CI:
216 $-7.38,-1.08$ for part-time job and $\beta=-5.17$; 95%CI: $-7.98,-2.36$ for unemployed), having HIV
217 positive serostatus ($\beta=-7.10$; 95%CI: $-9.23,-4.98$), aged ≥ 50 years ($\beta=-12.78$; 95%CI: $-17.56,-$
218 8.01) and having hazardous ATS use ($\beta=-5.97$; 95%CI: $-8.60,-3.35$). Whereas, patients who
219 finished secondary school or above had higher EQ-VAS scores than those who did not. (Table 6)

220 **(Table 6 is about here)**

221 **Discussion**

222 The mean score of EQ-5D-5L and EQ-VAS in our study were 0.96 (SD = 0.12) and 75.8
223 (SD=15.5), respectively, which were higher than that of the methadone patients in the North
224 mountain area in Vietnam 0.88 (SD = 0.20) and long-term treatment with methadone patients in
225 Norway 0.699 (0.25) (Nguyen et al. 2017b). This difference could happen due to the differences
226 in geographical location, social distinctions, economic status, and culture.

227 Our results indicated that MMT patients aged from 30 to 50 years old usually did not experience
228 significant pain/discomfort and anxiety/depression symptoms in their daily life. These symptoms
229 were more frequently reported among patients who were lower than 30 or older than 50 years old.

230 This finding was consistent with the previous study in Vietnam, in which, the prevalence of
231 anxiety/depression was the most common symptom among study participants (Tran et al. 2011).

232 The two problems (pain/discomfort and anxiety/depression) were also the most frequently reported
233 by MMT patients in Poland (Golicki and Niewada 2017). Notably, 77.8% of participants in our
234 study reported with the health states as 11111 (perfect health state) indicated that the quality of life
235 among MMT patients in Vietnam was relatively high.

236 We found that the patient's age, education, marital status, employment status, and socioeconomic
237 status were significantly associated with their HRQoL. Specifically, the HRQoL scores were lower
238 among older patients, which is in line with previous research in Vietnam, Uruguay, England and
239 Germany (Augustovski et al. 2016; Feng et al. 2015; Hinz et al. 2014). Patients with higher
240 education, being employed, and having high socioeconomic had higher HRQoL than the other
241 groups. It could be explained that people with stable income and jobs are easier to access MMT
242 services, and people with higher education are more likely to adopt/adherence the MMT treatment
243 and have the self-awareness to break the addiction (Quyen et al. 2020; Sadeghi et al. 2017).

244 Consistent with previous studies, our study revealed patients involving in the MMT program more
245 than five years had lower score of EQ-VAS as compared to those being treated in less than 5 years.
246 (Babaie and Razeghi 2013; Quyen et al. 2020). The results also showed patients who missed dose
247 had a higher score than adherence patients. Since the causal relationship has not been confirmed
248 yet, this finding raises the question that MMT treatment effective may lead to miss dose decision
249 in MMT patient.

250 In the present study, 33.9% of participants had HIV, and 96.8% of them were on ARV treatment,
251 among these, we found patients living with HIV had lower HRQoL. According to previous studies,
252 comorbidities contribute to lower HRQoL because they lead to poorer health status (Tran 2012;
253 Tran et al. 2011; Wang et al. 2014). ARVs have the effect of inhibiting the reproduction of HIV
254 but can bring side effects for the users. Therefore, it is as expected that the lower HRQoL scores
255 were found among these patients. However, the most difficult thing that these patients had to face
256 was experiencing social stigma and discrimination (Quyen et al. 2020).

257 Besides, HIV patients also bear the burden of treatment-related costs and are limited in daily
258 activities (Wang et al. 2014). In Vietnam, health insurance does not cover the costs of daily

259 consumables that methadone used but pays for routine laboratory tests and costs for treatment of
260 adverse effects and comorbidities in compliance with regulations by Vietnam's Ministry of Health.
261 Accordingly, drug users with insurance when participating in MMT are less worried about paying
262 additional treatment and laboratory test costs. The previous study has shown this policy helps
263 insurance patients sought and received treatment more promptly, sufficiently, and properly than
264 those who had to pay for treatment by themselves (Quyen et al. 2020).

265 In our study, patients being hazardous ATS users had lower EQ-VAS scores than their
266 counterparts. A previous study demonstrated that drug use among MMT patients was still a rising
267 problem that could decrease their health and quality of life (Le et al. 2021). Long-term ATS use
268 negatively leads to intoxication, emotional disorder, anxiety and increases high-risk sexual
269 behaviors such as unprotected sex and sex with multiple partners (Radfar and Rawson 2014;
270 Volkow et al. 2007). Our finding indicates the need for programs on controlling ATS use among
271 MMT patients, including screening, provide urine testing for the patient as a regular test. Besides,
272 other interventions to help patients withdraw from ATS are needed to maintain better outcomes
273 for MMT patients (Shariatirad et al. 2013).

274 Our study has several limitations. First, as a cross-sectional survey, the results could not be
275 interpreted as causal relationship. Second, as all the participants are recruited in Ho Chi Minh City,
276 the results might not be generalized for MMT patients in other areas. Further studies in Vietnam
277 are needed to thoroughly explore the associated factors with HRQoL among MMT patients,
278 including the different elements between male and female patients, social stigma, or psychology
279 events that could affect HRQoL.

280

281 **Conclusion**

282 HRQoL measurement provides valuable information for the policymaker to adopt suitable
283 decisions on opioid dependence treatment. The finding shows that patients with education, job
284 situation, and socioeconomic status are the related elements with higher HRQoL, which suggested
285 that the policymakers and physicians should pay more attention to these aspects while working on
286 treatment plan for drug users.

287 **Conflict of interest**

288 The authors declare that they have no conflict of interest.

289

290 **References**

- 291 Astals M, Domingo-Salvany A, Buenaventura CC, Tato J, Vazquez JM, Martín-Santos R, Torrens
292 M (2008) Impact of substance dependence and dual diagnosis on the quality of life of
293 heroin users seeking treatment *Subst Use Misuse* 43:612-632
294 doi:10.1080/10826080701204813
- 295 Augustovski F et al. (2016) An EQ-5D-5L value set based on Uruguayan population preferences
296 *Qual Life Res* 25:323-333 doi:10.1007/s11136-015-1086-4
- 297 Babaie E, Razeghi N (2013) Comparing the effects of methadone maintenance treatment,
298 therapeutic community, and residential rehabilitation on quality of life and mental health
299 of drug addicts *Addict Health* 5:16-20
- 300 EuroQol Research Foundation (2019) EQ-5D-5L User Guide. Rotterdam, Netherlands
- 301 Feng Y, Devlin N, Herdman M (2015) Assessing the health of the general population in England:
302 how do the three- and five-level versions of EQ-5D compare? *Health Qual Life Outcomes*
303 13:171 doi:10.1186/s12955-015-0356-8
- 304 Golicki D, Niewada M (2017) EQ-5D-5L Polish population norms *Arch Med Sci* 13:191-200
305 doi:10.5114/aoms.2015.52126
- 306 Herget G (2005) Methadone and buprenorphine added to the WHO list of essential medicines.
307 Canada
- 308 Hinz A, Kohlmann T, Stöbel-Richter Y, Zenger M, Brähler E (2014) The quality of life
309 questionnaire EQ-5D-5L: psychometric properties and normative values for the general
310 German population *Qual Life Res* 23:443-447 doi:10.1007/s11136-013-0498-2
- 311 Karow A, Verthein U, Pukrop R, Reimer J, Haasen C, Krausz M, Schäfer I (2011) Quality of life
312 profiles and changes in the course of maintenance treatment among 1,015 patients with

313 severe opioid dependence Subst Use Misuse 46:705-715
314 doi:10.3109/10826084.2010.509854

315 Korthuis T et al. (2008) Health-Related Quality of Life in HIV-Infected Patients: The Role of
316 Substance Use AIDS patient care and STDs 22:859-867 doi:10.1089/apc.2008.0005

317 Lashkaripour K, Bakhshani NM, Sadjadi SA (2012) Quality of life in patients on methadone
318 maintenance treatment: a three-month assessment J Pak Med Assoc 62:1003-1007

319 Le NT et al. (2021) Prevalence of Amphetamine-Type Stimulant Use and Related Factors among
320 Methadone Maintenance Patients in Ho Chi Minh City Vietnam: A Cross-Sectional Study
321 Journal of psychoactive drugs:1-9 doi:10.1080/02791072.2020.1871126

322 MOH (2020) Draft Guide to pilot implementation of multi-day methadone supply for patients
323 receiving opioid addiction treatment. Vietnamese Ministry of Health,

324 Nguyen LH et al. (2017a) Quality of life and healthcare service utilization among methadone
325 maintenance patients in a mountainous area of Northern Vietnam Health and quality of life
326 outcomes 15:77

327 Nguyen LH et al. (2017b) Quality of life and healthcare service utilization among methadone
328 maintenance patients in a mountainous area of Northern Vietnam Health Qual Life
329 Outcomes 15:77 doi:10.1186/s12955-017-0633-9

330 Nguyen LH et al. (2017c) Psychological Distress Among Methadone Maintenance Patients in
331 Vietnamese Mountainous Areas AIDS Behav 21:3228-3237 doi:10.1007/s10461-017-
332 1779-5

333 O'Donnell J, Vogenberg FR (2011) Applying legal risk management to the clinical use of
334 methadone P T 36:813-822

- 335 Quyen BTT, Nguyen LT, Phuong VTV, Hoang LT (2020) Quality of life in methadone
336 maintenance treated patients in Long An, a southern province of Vietnam *Health Psychol*
337 *Open* 7:2055102920953053-2055102920953053 doi:10.1177/2055102920953053
- 338 Radfar SR, Rawson RA (2014) Current research on methamphetamine: epidemiology, medical
339 and psychiatric effects, treatment, and harm reduction efforts *Addict Health* 6:146-154
- 340 Sadeghi N, Davaridolatabadi E, Rahmani A, Ghodousi A, Ziaeirad M (2017) Quality of life of
341 adolescents and young people arrive at an addiction treatment centers upon their admission,
342 and 1, 4 and 8 months after methadone maintenance therapy *J Educ Health Promot* 6:95-
343 95 doi:10.4103/jehp.jehp_297_13
- 344 Shariatirad S, Maarefvand M, Ekhtiari H (2013) Methamphetamine use and methadone
345 maintenance treatment: an emerging problem in the drug addiction treatment network in
346 Iran *Int J Drug Policy* 24:e115-116 doi:10.1016/j.drugpo.2013.05.003
- 347 Strada L, Vanderplasschen W, Buchholz A, Schulte B, Muller AE, Verthein U, Reimer J (2017)
348 Measuring quality of life in opioid-dependent people: a systematic review of assessment
349 instruments *Qual Life Res* 26:3187-3200 doi:10.1007/s11136-017-1674-6
- 350 Tran BX (2012) Quality of life outcomes of antiretroviral treatment for HIV/AIDS patients in
351 Vietnam *PloS one* 7:e41062-e41062 doi:10.1371/journal.pone.0041062
- 352 Tran BX, Nguyen LH, Nguyen CT, Latkin CA (2018) Health-related work productivity loss is low
353 for patients in a methadone maintenance program in Vietnam *The International journal on*
354 *drug policy* 60:1-7 doi:10.1016/j.drugpo.2018.07.007
- 355 Tran BX, Ohinmaa A, Nguyen LT (2012) Quality of life profile and psychometric properties of
356 the EQ-5D-5L in HIV/AIDS patients *Health and Quality of Life Outcomes* 10:132
357 doi:10.1186/1477-7525-10-132

- 358 Tran BX, Ohinmaa A, Nguyen LT, Nguyen TA, Nguyen TH (2011) Determinants of health-related
359 quality of life in adults living with HIV in Vietnam AIDS care 23:1236-1245
360 doi:10.1080/09540121.2011.555749
- 361 Vietnamese Ministry of Health FU (2014) Evaluate the effectiveness of methadone treatment for
362 opioid addiction treatment in Hai Phong and Ho Chi Minh City for the period 2009-2011.
- 363 Volkow ND, Wang GJ, Fowler JS, Telang F, Jayne M, Wong C (2007) Stimulant-induced
364 enhanced sexual desire as a potential contributing factor in HIV transmission The
365 American journal of psychiatry 164:157-160 doi:10.1176/ajp.2007.164.1.157
- 366 Wang Y et al. (2014) Reduced responses to heroin-cue-induced craving in the dorsal striatum:
367 effects of long-term methadone maintenance treatment Neurosci Lett 581:120-124
368 doi:10.1016/j.neulet.2014.08.026
- 369 World Health O (2004) Proposal for the inclusion of methadone in the WHO model list of essential
370 medicines.
- 371 World Health Organization (WHO) (2010) The Alcohol, Smoking and Substance Involvement
372 Screening Test (ASSIST). Switzerland
- 373

374 **Table 1: Demographic characteristics of respondents**

Characteristics	Total n	%
Gender	967	
Male	869	89.9
Female	98	10.1
Age	961	
< 30	111	11.6
30 - 49	786	81.8
≥ 50	64	6.6
Education	966	
Primary school or less	210	21.7
Secondary school	462	47.8
High school or above	294	30.4
Occupation	967	
Full-time job	718	74.3
Part-time job	108	11.2
Unemployed	141	14.5
Marital status	966	
Single	363	37.6
Married/live with partners	448	46.4
Divorced/Separated/ Widowed	155	16.0
Monthly income	965	
< 4 million VND	330	34.2
4 - 8 million VND	432	44.8
> 8 million VND	203	21.0
Ever injected drugs	967	
Yes	754	78.0
No	213	22.0
Injecting drug use within the past 3 months	965	
Yes	120	12.4
No	845	87.6
Duration on MMT	965	
< 1 year	128	13.3
1-5 years	580	60.1
> 5 years	257	26.6
Daily Methadone dose (mg)	967	
< 60 mg/day	245	25.3
60 - 120 mg/day	398	41.2
>120 mg/day	324	33.5

Characteristics	Total n	%
Dose missed in the last 3 months	967	
Yes	433	44.8
No	534	55.2
HIV positive	967	
Yes	328	33.9
No	639	66.1
ARV treatment	312	
Yes	302	96.8
No	10	3.2
Tuberculosis	967	
Yes	10	1.0
No	957	99.0
Hepatitis B	967	
Yes	94	9.7
No	873	90.3
Hepatitis C	967	
Yes	405	41.9
No	562	58.1

375

376 Notes: n, number of participants; MMT, methadone maintenance treatment; ARV, antiretroviral
377 treatment.

378 **Table 2: Profiles of EQ-5D-5L by age group**

Domains	< 30		30-49		≥ 50		Total	
	n	%	n	%	n	%	n	%
Mobility	111		786		64		967	
No problems	102	91.9	741	94.2	54	84.4	902	93.3
Slight problems	6	5.4	29	3.7	3	4.7	38	3.9
Moderate problems	2	1.8	8	1.0	3	4.7	14	1.5
Severe problems	1	0.9	7	1.0	4	6.3	12	1.2
Unable to walk	0	0.0	1	0.1	0	0.0	1	0.1
Self-care	111		786		64		967	
No problems	108	97.3	767	97.5	60	93.8	940	97.2
Slight problems	1	0.9	9	1.2	1	1.6	11	1.2
Moderate problems	2	1.8	6	0.8	2	3.0	9	0.9
Severe problems	0	0.0	3	0.4	1	1.6	6	0.6
Extreme problems	0	0.0	1	0.1	0	0.0	1	0.1
Usual activities	111		786		64		967	
No problems	100	90.1	734	93.3	58	90.6	897	92.8
Slight problems	7	6.3	32	4.1	1	1.6	40	4.1
Moderate problems	2	1.8	15	1.9	3	4.7	21	2.2
Severe problems	2	1.8	3	0.4	2	3.1	7	0.7
Unable to do	0	0.0	2	0.3	0	0.0	2	0.2
Pain/Discomfort	111		786		64		967	
No pain	97	87.4	682	86.7	45	70.3	829	85.8
Slight pain	10	9.0	70	8.9	8	12.5	88	9.1
Moderate pain	2	1.8	28	3.6	8	12.5	39	4.0
Severe pain	2	1.8	4	0.5	2	3.1	8	0.8
Extreme pain	0	0	2	0.3	1	1.6	3	0.3
Anxiety/Depression	111		786		64		967	
Not anxious/depressed	94	84.7	682	86.7	50	78.1	831	85.9
Slightly	14	12.6	72	9.2	8	12.5	94	9.8
Moderately	2	1.8	24	3.1	3	4.7	30	3.1
Severely	1	0.9	5	0.6	2	3.1	8	0.8
Extremely	0	0	3	0.4	1	1.6	4	0.4

379

380

381 **Table 3: EQ-5D-5L utility scores and EQ-VAS scores by different characteristics**

	EQ-5D-5L scores			EQ-VAS scores		
	Mean	SD	p-value	Mean	SD	p-value
Total	0.96	0.12		75.8	15.5	
Gender						
Male	0.96	0.11	0.249	75.8	15.2	0.949
Female	0.94	0.19		75.7	17.7	
Age						
< 30	0.96	0.11	<0.001	79.9	15.5	<0.001
30 - 49	0.96	0.11		75.9	15.1	
≥ 50	0.9	0.2		67.3	16.6	
Education						
Primary school or less	0.93	0.18	<0.001	72.2	17.1	<0.001
Secondary school	0.96	0.11		76.2	15.7	
High school or above	0.97	0.07		77.6	13.4	
Occupation						
Full-time job	0.97	0.1	<0.001	77.5	14.4	<0.001
Part-time job	0.94	0.12		71.4	15.5	
Unemployed	0.91	0.19		70.5	18.6	
Marital status						
Single	0.97	0.09	0.058	76.2	15.1	0.791
Married/live with partners	0.95	0.13		75.6	15.3	
Divorced/Separated/ Widowed	0.94	0.15		75.3	16.9	
Monthly income						
< 4 million VND	0.93	0.17	<0.001	72.2	17.6	<0.001
4 - 8 million VND	0.97	0.08		77.1	14.1	
> 8 million VND	0.97	0.08		79	13.5	
Ever injected drugs						
Yes	0.96	0.12	0.62	75	15.6	0.005
No	0.96	0.12		78.4	14.9	
Injecting drug use within the past 3 months						
Yes	0.95	0.09	0.818	73.3	16.7	0.059
No	0.96	0.12		76.1	15.3	
Duration on MMT						
< 1 year	0.97	0.09	0.645	77.6	14.7	0.01
1-5 years	0.95	0.13		76.5	15.5	
> 5 years	0.96	0.11		73.4	15.7	
Daily Methadone dose (mg)						

	EQ-5D-5L scores			EQ-VAS scores		
	Mean	SD	p-value	Mean	SD	p-value
< 60 mg/day	0.96	0.10	0.138	77.8	14.8	<0.001
60 - 120 mg/day	0.96	0.10		76.7	15.5	
>120 mg/day	0.95	0.15		73.2	15.6	
Dose missed in the last 3 months						
Yes	0.97	0.1	0.047	76.4	14.5	0.271
No	0.95	0.13		75.3	16.2	
HIV positive						
Yes	0.94	0.15	0.017	71.1	15.8	<0.001
No	0.96	0.1		78.2	14.8	
ARV treatment (n=312)						
Yes	0.94	0.15	<0.001	70.3	15.7	0.012
No	0.99	0.03		83	10.3	
Tuberculosis						
Yes	0.9	0.31	0.589	74.5	13	0.791
No	0.95	0.12		75.8	15.5	
Hepatitis B						
Yes	0.94	0.16	0.315	72	15.2	0.013
No	0.96	0.11		76.2	15.5	
Hepatitis C						
Yes	0.96	0.12	0.529	74.3	15.6	0.013
No	0.95	0.12		76.8	15.3	

382

383

384 **Table 4: EQ-5D-5L utility scores and EQ-VAS scores by different substance uses**

	EQ-5D-5L scores			EQ-VAS scores		
	Mean	SD	p-value	Mean	SD	p-value
Hazardous tobacco use (ASSIST \geq 4)						
Yes (n=941)	0.96	0.11	0.418	75.8	15.5	0.954
No (n=26)	0.91	0.31		76.0	14.3	
Hazardous alcohol use (ASSIST \geq 11)						
Yes (n=81)	0.95	0.09	0.707	76.0	15.2	0.888
No (n=886)	0.96	0.12		75.8	15.5	
Hazardous ATS use (ASSIST \geq 4)						
Yes (n=161)	0.95	0.13	0.251	71.7	17.0	<0.001
No (n=806)	0.96	0.12		76.6	15.1	
Positive urine test with ATS						
Yes (n=246)	0.96	0.11	0.491	76.4	14.7	0.490
No (n=721)	0.96	0.12		75.6	15.8	
Hazardous opioids use (ASSIST \geq 4)						
Yes (n=825)	0.96	0.12	0.171	75.7	15.5	0.564
No (n=142)	0.94	0.14		76.5	15.5	
Hazardous cannabis use (ASSIST \geq 4)						
Yes (n=25)	0.91	0.16	0.112	69.6	13.7	0.043
No (n=942)	0.96	0.12		76.0	15.5	

385

386 Notes: ASSIST, The Alcohol, Smoking and Substance Involvement Screening Test

387 **Table 5: Most frequent EQ-5D-5 L health states with mean utility scores and EQVAS**
388 **scores**

Health states	Number	Percent	Cum%	Mean Utility	Mean VAS
11111	752	77.8	77.8	1.00	78.5
11112	37	3.8	81.6	0.94	74.6
11121	28	2.9	84.5	0.92	65.5
11122	20	2.1	86.6	0.85	72.4
11131	16	1.7	88.3	0.85	55.6
11211	7	0.7	89.0	0.95	71.4
11113	7	0.7	89.7	0.89	76.4
21111	6	0.6	90.3	0.93	80.0
11222	5	0.5	90.8	0.81	70.0
11221	5	0.5	91.3	0.87	67.0

389

390

391 **Table 6: Multivariate linear regression model of factors related to EQ-5D-5L and EQ-VAS**
 392 **scores**

	EQ-5D-5L scores			EQ-VAS scores		
	β	95%CI	p-value	β	95%CI	p-value
Age	-	-	-			
< 30				1		
30 - 49				-2.45	[-5.59; 0.69]	0.126
≥ 50				-12.78	[-17.56; -8.01]	<0.001
Education	-	-	-			
Primary school or less				1		
Secondary school				2.92	[0.41; 5.43]	0.023
High school or above				3.71	[0.98; 6.45]	0.008
Marital status						
Single	1					
Married/live with partners	-0.08	[-0.14; -0.01]	0.021			
Divorced/Separated/ Widowed	-0.09	[-0.17; -0.01]	0.045			
Occupation						
Full-time job	1			1		
Part-time job	-0.10	[-0.19; -0.01]	0.031	-4.24	[-7.38; -1.08]	0.008
Unemployed	-0.09	[-0.18; -0.01]	0.066	-5.17	[-7.98; -2.36]	<0.001
Monthly income				-	-	-
< 4 million VND	1					
4 - 8 million VND	0.12	[0.04; 0.20]	0.003			
> 8 million VND	0.12	[0.02; 0.21]	0.013			
HIV positive						
No	1			1		
Yes	-0.07	[-0.13; -0.01]	0.036	-7.10	[-9.23; -4.98]	<0.001
Hazardous ATS use	-	-	-			
No				1		
Yes				-5.97	[-8.60; -3.35]	<0.001

393

394 Notes: CI, confidence interval

395

396

397

398